Medical Innovation Exchange

RQM+ Appoints Mahofski as Head of Mergers and Acquisitions



Ronnie Mahofski is the new head of mergers and acquisitions (M&A) at RQM+, a global provider of MedTech regulatory and quality experts.

Mahofski has more than 20 years of experience in the MedTech industry and has held various positions at RQM+, including overseeing M&A integration and business development. He previously served as VP of engineering for Circadiance and as a project manager for MEDRAD. In his new role at RQM+, Mahofski is responsible for identifying and pursuing acquisition opportunities that complement its core regulatory services and provide a comprehensive range of fully integrated outsourced solutions to help get MedTech products to market faster and ensure ongoing regulatory compliance.

“We’re rapidly becoming the organization that will help medical device companies connect the dots from concept through market deployment and maintenance, expediting patient access to life-improving technologies,” said Mahofski. “In the coming years, we will continue to expand our offerings to support MedTech customers throughout the product lifecycle. They recognize the significant time and cost savings they can achieve by running many key processes in parallel through one trusted partner.”

Mahofski started his career as a nuclear submarine junior officer on the USS Tennessee. He earned his bachelor’s degree in systems engineering at the U.S. Naval Academy and his Master of Business Administration, with a concentration in finance, from Waynesburg University.


Related Articles

  • RQM plus logo

    Jordi labs and its team of Ph.D. analytical chemists developed a proprietary, multi-detector approach to ensure that all extractables are accurately characterized to comply with global materials testing regulatory requirements.

  • FDA

    Highlights include leveraging big data, streamlining clinical trial design, reducing healthcare-associated infections and toughening up on cybersecurity.

  • Susan Alpert, SFA Consulting, Global Regulatory Strategy

    For companies in global markets, consider these three factors.

  • The agency is providing an easy way for people to report misconduct in the medical device industry.


Original post:

Post publish date:


Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!